An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Entecavir is a nucleoside analogue of 2-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naïve patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90% chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.

Original languageEnglish
Pages (from-to)177-186
Number of pages10
JournalExpert Review of Gastroenterology and Hepatology
Volume10
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Chronic Hepatitis B
Lamivudine
Infection
Hepatitis B virus
Therapeutics
Deoxyguanosine
Hepatitis B e Antigens
Liver Failure
Nucleosides
Hepatocellular Carcinoma
Histology
entecavir
Safety
Liver
DNA
adefovir

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{9fbff93fb93d4055b9e30c9dbd7012b4,
title = "An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults",
abstract = "Entecavir is a nucleoside analogue of 2-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-na{\"i}ve patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90{\%} chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.",
author = "Lee, {Hye Won} and Junyong Park and SangHoon Ahn",
year = "2016",
month = "2",
day = "1",
doi = "10.1586/17474124.2016.1125781",
language = "English",
volume = "10",
pages = "177--186",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "2",

}

An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. / Lee, Hye Won; Park, Junyong; Ahn, SangHoon.

In: Expert Review of Gastroenterology and Hepatology, Vol. 10, No. 2, 01.02.2016, p. 177-186.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults

AU - Lee, Hye Won

AU - Park, Junyong

AU - Ahn, SangHoon

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Entecavir is a nucleoside analogue of 2-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naïve patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90% chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.

AB - Entecavir is a nucleoside analogue of 2-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naïve patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90% chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.

UR - http://www.scopus.com/inward/record.url?scp=84956727898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956727898&partnerID=8YFLogxK

U2 - 10.1586/17474124.2016.1125781

DO - 10.1586/17474124.2016.1125781

M3 - Article

C2 - 26610256

AN - SCOPUS:84956727898

VL - 10

SP - 177

EP - 186

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 2

ER -